# Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

> **NCT01050218** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 237 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful

## Interventions

- **DRUG:** Desvenlafaxine Succinate Sustained-Release (DVS SR)

## Key facts

- **NCT ID:** NCT01050218
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 237 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050218, "Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01050218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*